Literature DB >> 14670633

Rifampicin attenuates brain damage in focal ischemia.

Burak Yulug1, Ulkan Kilic, Ertugrul Kilic, Mathias Bähr.   

Abstract

Rifampicin is an antibacterial agent that is widely used in tuberculosis and leprosy therapy. Interestingly, some experimental studies indicate that rifampicin acts as a hydroxyl radical scavenger and a glucocorticoid receptor activator. In this study, the neuroprotective effect of rifampicin was evaluated after transient and permanent focal cerebral ischemia. Anaesthetized male C57BL/6j mice were submitted to permanent or transient thread occlusion of the middle cerebral artery (MCA). Reperfusion in transient ischemia was initiated 30 min later by thread retraction. Rifampicin or vehicle were applied intraperitoneally before permanent or immediately after 30 min of transient ischemia. Later, 24 h after permanent or transient ischemia, animals were re-anesthetized and decapitated. Brain injury was evaluated by triphenyltetrazolium chloride staining (TTC), terminal transferase biotinylated-dUTP nick end labeling (TUNEL) and cresyl violet staining. A 20-mg/kg sample of rifampicin showed a significant neuroprotection after cerebral ischemia. The number of TUNEL-positive cells in the striatum, where disseminated tissue injury was observed, was also reduced by application of rifampicin as compared with vehicle-treated animals. The present report shows that administration of rifampicin efficiently reduces brain injury after permanent and transient focal cerebral ischemia in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14670633     DOI: 10.1016/j.brainres.2003.10.012

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Christina Patrick; Anthony Adame; Monica Thukral; Clifford Shults; Eliezer Masliah
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

Review 2.  Rifampicin and Parkinson's disease.

Authors:  Wei Bi; Lihong Zhu; Xiuna Jing; Yanran Liang; Enxiang Tao
Journal:  Neurol Sci       Date:  2012-07-21       Impact factor: 3.307

3.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern
Journal:  Lancet Neurol       Date:  2014-02-05       Impact factor: 44.182

4.  Some aspects of the in vivo neuroprotective capacity of flavonoids: bioavailability and structure-activity relationship.

Authors:  Felicia Rivera; Jessika Urbanavicius; Elena Gervaz; Andrea Morquio; Federico Dajas
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

5.  Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.

Authors:  Isabel López-García; Domokos Gerő; Bartosz Szczesny; Petra Szoleczky; Gabor Olah; Katalin Módis; Kangling Zhang; Jungling Gao; Ping Wu; Lawrence C Sowers; Doug DeWitt; Donald S Prough; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2016-11-15       Impact factor: 8.739

Review 6.  Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.

Authors:  Jerel Fields; Wilmar Dumaop; T D Langford; Edward Rockenstein; E Masliah
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-08       Impact factor: 4.147

7.  Rifampicin improves neuronal apoptosis in LPS-stimulated co‑cultured BV2 cells through inhibition of the TLR-4 pathway.

Authors:  Wei Bi; Lihong Zhu; Xiuna Jing; Zhifen Zeng; Yanran Liang; Anding Xu; Jun Liu; Songhua Xiao; Lianhong Yang; Qiaoyun Shi; Li Guo; Enxiang Tao
Journal:  Mol Med Rep       Date:  2014-08-11       Impact factor: 2.952

8.  Targeted brain delivery of RVG29-modified rifampicin-loaded nanoparticles for Alzheimer's disease treatment and diagnosis.

Authors:  Ruiyi Zhou; Lihong Zhu; Zhaohao Zeng; Rixin Luo; Jiawei Zhang; Rui Guo; Lei Zhang; Qunying Zhang; Wei Bi
Journal:  Bioeng Transl Med       Date:  2022-08-26

9.  The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss.

Authors:  L Creed Pettigrew; Richard J Kryscio; Christopher M Norris
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

10.  Rifampicin Attenuated Global Cerebral Ischemia Injury via Activating the Nuclear Factor Erythroid 2-Related Factor Pathway.

Authors:  Beibei Chen; Huimin Cao; Lili Chen; Xuemei Yang; Xiaoyan Tian; Rong Li; Oumei Cheng
Journal:  Front Cell Neurosci       Date:  2016-11-29       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.